Print

National Comprehensive Cancer Network Collaborates with AVEO Pharmaceuticals, Inc. (AVEO) and Astellas Pharma Inc. (YPH.BE) on Innovative Cancer Research  
2/17/2012 6:45:06 AM

FORT WASHINGTON, Pa.--(BUSINESS WIRE)--The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced that it has entered into a collaboration with AVEO Pharmaceuticals, Inc. and Astellas Pharma Inc. (Tokyo: 4503) to develop oncology research protocols and trials examining tivozanib as a single agent and in combination with other drugs and biologics in the treatment of solid tumors. Tivozanib is a potent, selective, long half-life inhibitor of all three vascular endothelial growth factor (VEGF) receptors. The VEGF pathway plays a distinct role in angiogenesis, which is critical in the growth and survival of solid tumors. Positive top-line results from a Phase 3 clinical study in advanced renal cell carcinoma (RCC) have been reported, and the drug is also being evaluated in other tumors.
//-->